Strona główna / Informacje / Badania kliniczne
Badania kliniczne
Na tej stronie dowiesz się, czym są badania kliniczne, jaki jest ich cel i jak możesz się w nie zaangażować.
There are probably thousands of studies and trials taking place throughout the world into ALK-positive lung cancer. Many will be in the laboratory. All add to scientific knowledge.
A relatively small number of studies and trials will involve a drug being taken by a patient. Every clinical trial will have strict inclusion and exclusion criteria which means that they may not be available to some patients. Some clinical trials will be ALK+ specific while others will be open to non-ALK+ patients.
Because of inclusion and exclusion criteria, the results of clinical trials may not be replicated in the real world.
Phase I studies primarily assess the safety of a drug. They can be the very first time the drug has been administered to humans or it can be an approved drug that is being tested in a different type of cancer. A relatively small number of patients may be included at this stage. This initial phase of testing can last for several years because the trial design slowly increases the drug dose to identify the side effects before they are severe. The study will also determine how the drug(s) are absorbed, metabolized, and excreted.
Phase II studies primarily assess the efficacy of a drug. This second phase of testing can last several years. Some phase II studies are randomized trials where one group of patients receives the experimental drug while a second “control” group receives a standard treatment. This allows investigators to provide comparative information about the relative safety and effectiveness of the new drug.
Phase III studies are typically randomized studies with many hundreds of patients that can last many years. In the end, the information provides a more thorough understanding of the effectiveness of the drug, the benefits, and the range of possible adverse reactions.
Before a drug can be used in the UK, it must receive a marketing authorisation (product licence) from The Medicines and Healthcare products Regulatory Agency confirming that it meets standards of quality, safety, and efficacy.
Before a drug can be prescribed in the NHS, it must be approved by the National Institute for Health and Care Excellence (NICE) as being cost-effective. Scotland has a similar regulator.
Because targeted therapies can be very efective for ALK+ patients, newly diagnosed patients would not usually seek clinical trials until they had exhausted standard treatments. An exception might be the Neladalkib/Alectinib trial referred to below.
Clinical Trials in UK
Below are the clinical trials that we believe are currently available in the UK for ALK-positive patients and the detailed trial documents for each can be viewed. Interpreting inclusion and exclusion criteria requires medical knowledge and patients should consult their oncologists to establish whether or not they might be eligible for a trial. The trial information lists the location of hospitals that are participating in the trial.
We endeavour to keep information current but changes may occur of which we are not aware, e.g. recruitment to a trial may close or a hospital may cease participating. Please tell us if you become aware of changes that we need to make.
Nazwa
Streszczenie
Działanie
NVL-665 u pacjentów z zaawansowanym ALK-dodatnim rakiem płuca niedrobnokomórkowego
A new Phase 3 trial is open at several centres comparing Neladalkib (formerly NVL-655) with Alectinib as a first line treatment for newly diagnosed patients.. The report is not expected until 2030.
NVL-665 u pacjentów z zaawansowanym ALK-dodatnim rakiem płuca niedrobnokomórkowego
A study of NVL-655 in patients who have progressed on other TKis and patients who have not received a prior TKI. (ALKOVE-1).
A preliminary report is expected in October 2025 and a full report before the end of the year.
Although the study has closed, patients may still be able to access the drug under the Expanded Access Programme.
Bronchoskopia nawigacyjna do ablacji guzów płuc
A trial at the Royal Brompton into the use of robotic-controled brochoscopy to ablate tumours in the lung.
Immunoterapia lub terapia celowana z radiochirurgią stereotaktyczną lub bez niej u pacjentów z przerzutami do mózgu z niedrobnokomórkowego raka płuc
The primary objective of the study is to assess the efficacy of the combination of standard systemic treatment plus radiotherapy to the brain versus standard systemic treatment alone. The study will report in 2026.
Bronchoskopia nawigacyjna do ablacji guzów płuc
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab.
Bronchoskopia nawigacyjna do ablacji guzów płuc
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with BNT327 in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSCLC).
Bronchoskopia nawigacyjna do ablacji guzów płuc
UCB4594 is a type of drug called a monoclonal antibody. It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G) that is found in high levels on some cancer cells. By attaching itself to this protein it may help the immune system to attack and kill the cancer cells.
Bronchoskopia nawigacyjna do ablacji guzów płuc
Patients have received at least one TKI and platinum-based combination therapy or experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant, neoadjuvant, or chemoradiotherapy setting.
Bronchoskopia nawigacyjna do ablacji guzów płuc
£1.7 million for the world's first vaccine to prevent lung cancer.
Bronchoskopia nawigacyjna do ablacji guzów płuc
Therapeutic cancer vaccines aim to help the body’s immune system recognise the antigens found in cancer cells and to attack and destroy the cancer cells that have them.
Światowe badania i szlaki
Unfortunately, there is not a single registry of all clinical trials that are being conducted throughout the world. Below, are several sources of information on clinical trials.
Name
Streszczenie
Action
Clinicaltrials.gov
Arkusz kalkulacyjny Google zawierający informacje o bieżących badaniach klinicznych.
European Clinical Trials Register
Arkusz kalkulacyjny Google zawierający informacje o bieżących badaniach klinicznych.
ALK+ Trials/Studies
Arkusz kalkulacyjny Google zawierający informacje o bieżących badaniach klinicznych.
Clinical Net
Arkusz kalkulacyjny Google zawierający informacje o bieżących badaniach klinicznych.
ALK Positive Inc
Arkusz kalkulacyjny Google zawierający informacje o bieżących badaniach klinicznych.
Cancer Research UK
Arkusz kalkulacyjny Google zawierający informacje o bieżących badaniach klinicznych.
Artiificial Inteligence
Arkusz kalkulacyjny Google zawierający informacje o bieżących badaniach klinicznych.
Studies of Interest
Nazwa
Summary
Action
Podsumowanie badań nad szczepionkami w Wielkiej Brytanii
This document summarises information on vaccine Studies going on throughout the UK
ALINA: Skuteczność i bezpieczeństwo leczenia adiuwantowego Alectinibem w porównaniu z chemioterapią u pacjentów
Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ NSCLC
ALK Life Study - badanie podłużne
An ongoing study collecting data from patients globally.
Badanie CROWN Lorlatinib jako leczenie pierwszej linii
Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated.